Featured Research

from universities, journals, and other organizations

Anti-Clotting Drug Safer Than Aspirin At Averting Second Strokes

February 19, 2001
American Heart Association
An anti-clotting drug is as effective as aspirin at preventing a second stroke, but without the bleeding complication sometimes associated with aspirin use, according to two new studies.

FORT LAUDERDALE, Fla., Feb. 15 – An anti-clotting drug is as effective as aspirin at preventing a second stroke, but without the bleeding complication sometimes associated with aspirin use, according to two new studies. The studies were reported today at the American Stroke Association’s 26th International Stroke Conference. The American Stroke Association is a division of the American Heart Association.

The drug, known as triflusal, is currently unavailable in the United States – even for clinical research – because an application has never been filed with the Food and Drug Administration. Triflusal was developed in Spain about 20 years ago, where it has been widely used in the prevention of strokes and heart attacks. It also is licensed for use in Italy, Portugal, Greece, some parts of Asia and most of Latin America, including Mexico and Argentina.

A three-year, multi-center clinical trial in Buenos Aires (TAPIRSS – Triflusal versus Aspirin for the Prevention of Infarction: A Randomized Stroke Study) included 429 patients treated either with aspirin or triflusal for more than a year following an ischemic stroke (caused by a blocked blood vessel) or a transient ischemic attack (a "mini-stroke" or temporary vessel blockage).

They found comparable rates of death, strokes and heart attacks in both groups. The rate of death from cardiovascular disease was 3.7 percent for those taking aspirin compared to 2.3 percent for those on triflusal. About 7.4 percent of the aspirin group and 8 percent of the triflusal group suffered a stroke; 2.3 percent of the aspirin group and 1.9 percent of the triflusal group had non-fatal heart attacks.

But the combined rate of severe and non-severe bleeding in the brain and elsewhere was only 2.8 percent among those taking triflusal compared to 8.3 percent among those taking aspirin.

"In our study, triflusal had a stroke preventive effect as potent as that of aspirin without the damaging hemorrhagic complications in the brain and other parts of the body that can limit the use of aspirin in some stroke patients," says Antonio Culebras, M.D., Ph.D., lead author of the study, professor of neurology at Upstate Medical University and director of the Clinical Stroke Research Center of the Veterans Affairs Medical Center in Syracuse, N.Y. "Therefore, it can be safely used in the 10 percent to 20 percent of individuals in whom aspirin causes bleeding, or in those older than 85, who are more prone to bleeding when taking aspirin."

Triflusal has a chemical structure very similar to aspirin and, like aspirin, prevents platelets in the blood from clumping together to form clots that can block arteries – which can lead to stroke. But unlike aspirin, triflusal has a component that makes it less likely to cause bleeding.

A second clinical trial, the Triflusal Aspirin Cerebral Infarction Prevention (TACIP) study, conducted in 43 centers in Spain and Portugal, evaluated the long term efficacy and safety of both drugs. Researchers treated more than 2,100 patients who had a mini stroke or non-disabling stroke with aspirin or triflusal for almost three years.

The incidence of stroke, heart attack or cardiovascular death was similar for the triflusal group and aspirin groups (13.1 percent and 12.4 –statistically insignificant). However, the incidence of bleeding was considerably higher in the group taking low-dose aspirin (24.5 percent) compared to the group taking triflusal (16.4 percent).

"We found that major and minor hemorrhages were significantly reduced by triflusal with a similar stroke preventive effect than aspirin," says Jordi Matias-Guiu, M.D., Ph.D., lead author and professor of neurology at Alicante Miguel Hernández University and head of the neurology department at Alicante General Hospital. "The results also show that the hemorrhagic risk of aspirin is markedly increased after the second year of treatment.

"We conclude that triflusal is a safer and preferable alternative to low-dose aspirin in the long-term prevention of recurrent stroke and other vascular events," says Culebras. "If the results of these clinical trials performed outside the United States are accepted as proof of its clinical value, it could be approved at some point in the future for use in the United States. "It would be interesting to compare other antiplatelet agents to triflusal in the future," he says.

The American Stroke Association cautions that larger trials are still required to prove triflusal’s efficacy, but notes these important trials offer promising potential for individuals unable to take aspirin.

"The overall results of these trials favored aspirin," says Gregory Albers, M.D. an association spokesperson. "Therefore, larger trials will be required to more precisely define the efficacy of this compound. However, the clear and statistically significant benefit of triflusal in both major and minor bleeding suggests that triflusal may be an ideal therapy for patients who are unable to take other antiplatelet agents because of bleeding complications."

Culebras’ co-investigators in the Buenos Aires study include R. Rotta-Escalante, M.D.; J. Vila, M.D.; R. Domínguez, M.D.; G. Abiusi, M.D.; A. Famulari, M.D.; R. Rey; L. Bauso-Toselli, M.D.; H. Gori, M.D.; J. Ferrari, M.D.; and H. Fraiman, M.D. The executive committee of TACIP include José Ferro, M.D., Ph.D.; José Alvarez-Sabin, M.D., Ph.D.; and Ferrán Torres, M.D., Ph.D.

Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.

Cite This Page:

American Heart Association. "Anti-Clotting Drug Safer Than Aspirin At Averting Second Strokes." ScienceDaily. ScienceDaily, 19 February 2001. <www.sciencedaily.com/releases/2001/02/010216081552.htm>.
American Heart Association. (2001, February 19). Anti-Clotting Drug Safer Than Aspirin At Averting Second Strokes. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2001/02/010216081552.htm
American Heart Association. "Anti-Clotting Drug Safer Than Aspirin At Averting Second Strokes." ScienceDaily. www.sciencedaily.com/releases/2001/02/010216081552.htm (accessed July 30, 2014).

Share This

More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) — The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News


      Free Subscriptions

      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile

      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?

      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins